A N N O U N C I N G
Blue Ocean
Clinical Research
MICHAEL TOLENTINO, MD
New research and clinical trials
aim to detect, prevent and slow
the progression of Dry Age
Related Macular Degeneration.
Tampa Bay retinal specialists and surgeons, D.M. Deupree, MD, FACS,
and Michael Tolentino, MD, are excited to announce the opening of
Blue Ocean Clinical Research Center (BOCR). Located at The Macula
Center (TMC) in Clearwater, BOCR is a state-of-the-art facility that
focuses on groundbreaking research in eye disease.
BOCR's mission is to develop and provide
patients with preventative, therapeutic
and sight-restoring strategies
for visually impairing diseases such
as macular degeneration, diabetic
retinopathy, glaucoma and uveitis.
DRY AGE RELATED MACULAR
DEGENERATION.
BOCR's current focus is on dry
age related macular degeneration.
Macular Degeneration, often called
age-related macular degeneration
(AMD), is the leading cause of central
vision impairment in Americans over
65 years of age. It is an eye disease
that damages the macula—the part of
the eye responsible for sharp, central
vision. There are two classifications
of macular degeneration: dry and
wet – Currently there are effective eye
injection treatments for the wet form
developed by TMC doctors, but there is
no proven treatment for the dry form.
Doctors at TMC/BOCR are developing
strategies such as triple carotenoid
supplementation and true blue light
protection (True Blue Lens™) to
prevent the development of and loss
of vision from macular degeneration.
BOCR doctors are also in the forefront
of detecting macular degeneration in
patients who are symptomless or who
have relatives who lost vision from
AMD, by utilizing advanced technologies
such as AdaptDX™, OCT angiography,
DNA testing and Foresee™
Home monitoring devices.
For patients who have advanced dry
macular degeneration, also known
as geographic atrophy (GA), there
28 COMMUNITY HEALTHCARE DIGEST • OCT–DEC 2018 | WWW.CHDIGEST.COM
/WWW.CHDIGEST.COM